Exploring FIB-4 for Fibrosis Risk Assessment

In this sixth episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we share insight on primary fibrosis risk assessment using the FIB-4 index in patients with MASH (metabolic dysfunction-associated steatohepatitis). Our experts explain the importance of noninvasive tests as a useful tool to identify patients at high risk for MASH. Futhermore, they discuss the relevance of using the FIB-4 test in order to facilitate timely intervention for these at-risk patients. This episode is brought to you by Novo Nordisk Inc.